Smith Jeffrey T L

EVP & Chief Medical Officer

Smith Jeffrey T L has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jan 12, 2026.

On the most recent filing, Smith Jeffrey T L is listed as EVP & Chief Medical Officer at Zymeworks Inc. Inside the rolling window, Smith Jeffrey T L reported no open-market purchases and 2 open-market sales totaling $476K in ZYME. The largest disclosed transaction in the window is a sale of 10,538 ZYME shares on Jan 5, 2026, worth $264K.

Companies traded

Other insiders at ZYME

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$476K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ZYMESale$211KJan 12SEC ↗
ZYMESale$264KJan 5SEC ↗
Showing 1–2 of 2
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Smith Jeffrey T L made?

Smith Jeffrey T L has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.

Which companies does Smith Jeffrey T L trade?

Smith Jeffrey T L has filed SEC Form 4 disclosures for 1 company, including ZYME.

When was Smith Jeffrey T L's most recent SEC Form 4 filing?

Smith Jeffrey T L's most recent SEC Form 4 filing on Tracefour is dated Jan 12, 2026.

What is Smith Jeffrey T L's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Smith Jeffrey T L is listed as EVP & Chief Medical Officer.

What is Smith Jeffrey T L's total buy and sell value in the current window?

Inside the rolling retention window, Smith Jeffrey T L bought $0 and sold $476K based on SEC Form 4 filings.

What was Smith Jeffrey T L's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 10,538 ZYME shares on 2026-01-05, worth $264K, per SEC Form 4 filings.